Oppenheimer Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.6M | Buy |
66,504
+3,172
| +5% | +$597K | 0.13% | 177 |
|
|
2026
Q1 | $12.5M | Buy |
+63,332
| New | +$12.2M | 0.14% | 170 |
|
|
2025
Q4 | – | Sell |
-58,230
| Closed | -$8.93M | – | 1110 |
|
|
2025
Q3 | $8.93M | Buy |
58,230
+4,021
| +7% | +$609K | 0.1% | 228 |
|
|
2025
Q2 | $7.58M | Buy |
54,209
+6,207
| +13% | +$870K | 0.09% | 258 |
|
|
2025
Q1 | $7.06M | Sell |
48,002
-3,314
| -6% | -$479K | 0.09% | 251 |
|
|
2024
Q4 | $6.72M | Buy |
51,316
+5,327
| +12% | +$746K | 0.08% | 265 |
|
|
2024
Q3 | $7.17M | Buy |
45,989
+1,679
| +4% | +$271K | 0.09% | 247 |
|
|
2024
Q2 | $6.91M | Buy |
44,310
+602
| +1% | +$90.6K | 0.09% | 251 |
|
|
2024
Q1 | $5.92M | Sell |
43,708
-277
| -0.6% | -$36.7K | 0.09% | 254 |
|
|
2023
Q4 | $5.92M | Buy |
43,985
+7,554
| +21% | +$982K | 0.08% | 270 |
|
|
2023
Q3 | $4.93M | Buy |
36,431
+11,488
| +46% | +$1.57M | 0.08% | 284 |
|
|
2023
Q2 | $3.57M | Buy |
24,943
+3,045
| +14% | +$448K | 0.05% | 367 |
|
|
2023
Q1 | $3.04M | Buy |
21,898
+3,863
| +21% | +$520K | 0.05% | 387 |
|
|
2022
Q4 | $2.45M | Sell |
18,035
-642
| -3% | -$80.5K | 0.04% | 426 |
|
|
2022
Q3 | $2.05M | Buy |
18,677
+468
| +3% | +$59.4K | 0.04% | 442 |
|
|
2022
Q2 | $2.41M | Sell |
18,209
-3,857
| -17% | -$506K | 0.04% | 415 |
|
|
2022
Q1 | $2.93M | Buy |
22,066
+2,097
| +11% | +$251K | 0.04% | 419 |
|
|
2021
Q4 | $2.33M | Sell |
19,969
-1,137
| -5% | -$134K | 0.03% | 509 |
|
|
2021
Q3 | $2.54M | Buy |
21,106
+9,480
| +82% | +$1.1M | 0.04% | 457 |
|
|
2021
Q2 | $1.39M | Buy |
+11,626
| New | +$1.28M | 0.02% | 649 |
|
|
2020
Q4 | – | Sell |
-6,459
| Closed | -$708K | – | 1136 |
|
|
2020
Q3 | $708K | Sell |
6,459
-10,888
| -63% | -$1.21M | 0.01% | 713 |
|
|
2020
Q2 | $1.83M | Sell |
17,347
-4,094
| -19% | -$423K | 0.04% | 426 |
|
|
2020
Q1 | $1.92M | Sell |
21,441
-19,231
| -47% | -$1.81M | 0.05% | 363 |
|
|
2019
Q4 | $4.05M | Sell |
40,672
-26,405
| -39% | -$2.49M | 0.09% | 265 |
|
|
2019
Q3 | $5.98M | Sell |
67,077
-35,275
| -34% | -$3.06M | 0.13% | 192 |
|
|
2019
Q2 | $8.45M | Buy |
102,352
+471
| +0.5% | +$36.9K | 0.19% | 135 |
|
|
2019
Q1 | $8.24M | Sell |
101,881
-2,357
| -2% | -$186K | 0.19% | 136 |
|
|
2018
Q4 | $7.92M | Sell |
104,238
-8,498
| -8% | -$664K | 0.2% | 117 |
|
|
2018
Q3 | $8.92M | Sell |
112,736
-122,114
| -52% | -$9.24M | 0.2% | 128 |
|
|
2018
Q2 | $16.5M | Buy |
234,850
+3,947
| +2% | +$284K | 0.4% | 57 |
|
|
2018
Q1 | $16.1M | Buy |
230,903
+18,708
| +9% | +$1.3M | 0.41% | 54 |
|
|
2017
Q4 | $14.4M | Hold |
212,195
| – | – | 0.38% | 60 |
|
|
2017
Q3 | $14.4M | Buy |
212,195
+18,443
| +10% | +$1.17M | 0.37% | 61 |
|
|
2017
Q2 | $13.2M | Buy |
193,752
+459
| +0.2% | +$30K | 0.37% | 63 |
|
|
2017
Q1 | $12M | Buy |
+193,293
| New | +$11.3M | 0.34% | 73 |
|
Other funds holding AZN
EP
IA
Oppenheimer Asset Management's AZN Position: Q2 2026 in Review
Oppenheimer Asset Management increased its AstraZeneca (AZN) stake by 5% in Q2 2026, buying an estimated $597K and bringing the position to 66,504 shares worth $12.6M. The position accounts for 0.13% of the portfolio, ranked #177.
Oppenheimer Asset Management first reported a position in AZN in Q1 2017 and has held it in 35 quarters since. The position peaked at $16.5M in Q2 2018. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Oppenheimer Asset Management held 66,504 shares of AstraZeneca worth $12.6M as of Q2 2026.
- Oppenheimer Asset Management bought 3,172 AstraZeneca shares in Q2 2026, an estimated $597K.
- AstraZeneca made up 0.13% of Oppenheimer Asset Management's portfolio in Q2 2026, its #177 holding.
- Oppenheimer Asset Management first reported a position in AstraZeneca in Q1 2017 and has held it in 35 quarters since.
- Oppenheimer Asset Management's AstraZeneca position peaked at $16.5M in Q2 2018.
- 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.